Next, CSJ148, which consists of two anti-HCMV mAbs, an anti-gB mAb (LJP538) and an anti-pentamer mAb (LJP539) 201 , was evaluated in a phase II trial for prophylaxis of HCMV in patients undergoing haematopoietic stem cell transplantation 202 and also did not achieve the primary end point

Ingredients Water, Niacinamide, Sunflower Seed Oil, Glutathione (600mg), Peppermint Leaf Extract, Sulfate Primrose Extract, Yarrow Extract, Mallow Extract, Lemon Chestnut Extract, Speedwell Extract, Skyweed Root Extract, Indian Gooseberry Fruit Extract, Mulberry Bark Extract, Virginia Prunus Leaf Extract, Sodium Hyaluronate, Glyceryl Arachidonate, Glyceryl Linolinate, Panthenol, Tocopheryl Acetate, Sodium Ascorbyl Phosphate, Pyridoxine, Polyacid, Thiamine HCl, Cyanocobalamin, Biotin, Retinyl Palmitate, Acetylhexapeptide-8, Copper Tripeptide-1, Oligopeptide-29, Oligopeptide-32, Palmitoylpentapeptide-4, Cetearyl Olivate, Polyacrylamide, Sorbitan Oleate, 1-2-Hexanediol, Pasqueflower Extract, Cinnabar Fruit Extract, Russian Extract, C13-14 Isoparaffin, Fee, Carbomer, Triethanolamine, Glycerol, Laureth-7, Butylene Glycol, Ethylhexylglycerin, Hydrogenated Lecithin, Polyglyceryl-10 Stearate The manufacturer is responsible for the products ingredients
A., Culotta, V
Mitochondrial complex I inhibition in dopaminergic neurons causes altered protein profile and protein oxidation: implications for Parkinsons disease